Literature DB >> 31939276

Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Yazhe Wang1, Ying Xie1, Kameron V Kilchrist2, Jing Li1, Craig L Duvall2, David Oupický1.   

Abstract

Combination therapies consisting of multiple short therapeutic RNAs, such as small interfering RNA (siRNA) and microRNA (miRNA), have enormous potential in cancer treatment as they can precisely silence a specific set of oncogenes and target multiple disease-related pathways. However, clinical use of siRNA/miRNA combinations is limited by the availability of safe and efficient systemic delivery systems with sufficient tumor penetrating and endosomal escaping capabilities. This study reports on the development of multifunctional tumor-penetrating mesoporous silica nanoparticles (iMSNs) for simultaneous delivery of siRNA (siPlk1) and miRNA (miR-200c), using encapsulation of a photosensitizer indocyanine green (ICG) to facilitate endosomal escape and surface conjugation of the iRGD peptide to enable deep tumor penetration. Increased cell uptake of the nanoparticles was observed in both 3D tumor spheroids in vitro and in orthotopic MDA-MB-231 breast tumors in vivo. Using a galectin-8 recruitment assay, we showed that reactive oxygen species generated by ICG upon light irradiation functioned as an endosomolytic stimulus that caused release of the siRNA/miRNA combination from endosomes. Co-delivery of the therapeutic RNAs displayed combined cell killing activity in cancer cells. Systemic intravenous treatment of metastatic breast cancer with the iMSNs loaded with siPlk1 and miR-200c resulted in a significant suppression of the primary tumor growth and in marked reduction of metastasis upon short light irradiation of the primary tumor. This work demonstrates that siRNA-miRNA combination assisted by the photodynamic effect and tumor penetrating delivery system may provide a promising approach for metastatic cancer treatment.

Entities:  

Keywords:  iRGD; mesoporous silica nanoparticle; metastasis; photodynamic effect; siRNA−miRNA combination; tumor penetration

Mesh:

Substances:

Year:  2020        PMID: 31939276      PMCID: PMC7011569          DOI: 10.1021/acsami.9b21214

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  55 in total

Review 1.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

2.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

3.  Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.

Authors:  Jingga Morry; Worapol Ngamcherdtrakul; Shenda Gu; Moataz Reda; David J Castro; Thanapon Sangvanich; Joe W Gray; Wassana Yantasee
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

4.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

5.  Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness.

Authors:  Ying Xie; Cody J Wehrkamp; Jing Li; Yan Wang; Yazhe Wang; Justin L Mott; David Oupický
Journal:  Mol Pharm       Date:  2016-02-08       Impact factor: 4.939

6.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

Authors:  Yunching Chen; Xiaodong Zhu; Xiaoju Zhang; Bin Liu; Leaf Huang
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

7.  PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.

Authors:  Ying Xie; Hongzhi Qiao; Zhigui Su; Minglei Chen; Qineng Ping; Minjie Sun
Journal:  Biomaterials       Date:  2014-06-14       Impact factor: 12.479

8.  MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation.

Authors:  Jun Yu; Kenoki Ohuchida; Kazuhiro Mizumoto; Norihiro Sato; Tadashi Kayashima; Hayato Fujita; Kouhei Nakata; Masao Tanaka
Journal:  Mol Cancer       Date:  2010-06-28       Impact factor: 27.401

9.  Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide.

Authors:  Yuhuan Li; Robert J Lee; Kongtong Yu; Ye Bi; Yuhang Qi; Yating Sun; Yujing Li; Jing Xie; Lesheng Teng
Journal:  ACS Appl Mater Interfaces       Date:  2016-09-27       Impact factor: 9.229

Review 10.  RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

Authors:  Pedro Barata; Anil K Sood; David S Hong
Journal:  Cancer Treat Rev       Date:  2016-08-28       Impact factor: 12.111

View more
  24 in total

1.  Genetically Encoded Split-Luciferase Biosensors to Measure Endosome Disruption Rapidly in Live Cells.

Authors:  Kameron V Kilchrist; John William Tierney; Craig L Duvall
Journal:  ACS Sens       Date:  2020-07-13       Impact factor: 7.711

Review 2.  Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.

Authors:  Kah Min Yap; Mahendran Sekar; Shivkanya Fuloria; Yuan Seng Wu; Siew Hua Gan; Nur Najihah Izzati Mat Rani; Vetriselvan Subramaniyan; Chandrakant Kokare; Pei Teng Lum; M Yasmin Begum; Shankar Mani; Dhanalekshmi Unnikrishnan Meenakshi; Kathiresan V Sathasivam; Neeraj Kumar Fuloria
Journal:  Int J Nanomedicine       Date:  2021-12-02

Review 3.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

4.  Imaging Intracellular Drug/siRNA Co-Delivery by Self-Assembly Cross-Linked Polyethylenimine with Fluorescent Core-Shell Silica Nanoparticles.

Authors:  Ruirui Zhang; Shuang Wei; Leihou Shao; Lili Tong; Yan Wu
Journal:  Polymers (Basel)       Date:  2022-04-28       Impact factor: 4.967

5.  Recent advances in porous nanostructures for cancer theranostics.

Authors:  Jinping Wang; Beilu Zhang; Jingyu Sun; Wei Hu; Hongjun Wang
Journal:  Nano Today       Date:  2021-04-08       Impact factor: 18.962

Review 6.  Tiny miRNAs Play a Big Role in the Treatment of Breast Cancer Metastasis.

Authors:  Andrea York Tiang Teo; Xiaoqiang Xiang; Minh Tn Le; Andrea Li-Ann Wong; Qi Zeng; Lingzhi Wang; Boon-Cher Goh
Journal:  Cancers (Basel)       Date:  2021-01-18       Impact factor: 6.639

7.  Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Authors:  Huseyin Beyaz; Hasan Uludag; Doga Kavaz; Nahit Rizaner
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles.

Authors:  Miguel Gisbert-Garzarán; María Vallet-Regí
Journal:  Nanomaterials (Basel)       Date:  2020-05-09       Impact factor: 5.076

Review 9.  Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules.

Authors:  Rafael R Castillo; Daniel Lozano; María Vallet-Regí
Journal:  Pharmaceutics       Date:  2020-05-07       Impact factor: 6.321

Review 10.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.